Design Therapeutics, Inc. Research and Development Expense
Design Therapeutics, Inc. (DSGN) reported Research and Development Expense of $16.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-03
- Design Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $16.39M, a 4.13% increase year-over-year.
- Design Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $14.38M, a 6.49% decline year-over-year.
- Design Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $13.43M, a 10.43% increase year-over-year.
- Design Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $14.59M, a 22.84% increase year-over-year.
- Design Therapeutics, Inc. research and development expense for fiscal 2025 was $59.13M, a 33.32% increase from fiscal 2024.
- Design Therapeutics, Inc. research and development expense for fiscal 2024 was $44.35M, a 22.28% decline from fiscal 2023.
- Design Therapeutics, Inc. research and development expense for fiscal 2023 was $57.06M, a 17.38% increase from fiscal 2022.
- Design Therapeutics, Inc. research and development expense for fiscal 2022 was $48.61M, a 96.19% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.39M 10-Q · filed 2026-08-03 | $30.77M 10-Q · filed 2026-08-03 | $44.19M derived: sum of 3 quarters · filed 2026-08-03 | $58.78M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $14.38M 10-Q · filed 2026-04-28 | $27.80M derived: sum of 2 quarters · filed 2026-04-28 | $42.39M derived: sum of 3 quarters · filed 2026-04-28 | $58.13M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $13.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $28.01M derived: sum of 2 quarters · filed 2026-03-09 | $43.75M derived: sum of 3 quarters · filed 2026-08-03 | $59.13M 10-K · filed 2026-03-09 |
| 2025-09-30 | $14.59M 10-Q · filed 2025-11-05 | $30.33M derived: sum of 2 quarters · filed 2026-08-03 | $45.70M 10-Q · filed 2025-11-05 | $57.86M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $15.74M 10-Q · filed 2026-08-03 | $31.11M 10-Q · filed 2026-08-03 | $43.27M derived: sum of 3 quarters · filed 2026-08-03 | $55.15M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $15.38M 10-Q · filed 2026-04-28 | $27.53M derived: sum of 2 quarters · filed 2026-04-28 | $39.41M derived: sum of 3 quarters · filed 2026-04-28 | $49.93M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $24.03M derived: sum of 2 quarters · filed 2026-03-09 | $34.55M derived: sum of 3 quarters · filed 2026-03-09 | $44.35M 10-K · filed 2026-03-09 |
| 2024-09-30 | $11.88M 10-Q · filed 2025-11-05 | $22.39M derived: sum of 2 quarters · filed 2025-11-05 | $32.19M 10-Q · filed 2025-11-05 | $43.20M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $10.52M 10-Q · filed 2025-08-07 | $20.32M 10-Q · filed 2025-08-07 | $31.33M derived: sum of 3 quarters · filed 2025-08-07 | $44.59M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $9.80M 10-Q · filed 2025-05-07 | $20.81M derived: sum of 2 quarters · filed 2025-05-07 | $34.07M derived: sum of 3 quarters · filed 2025-05-07 | $51.13M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $11.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $24.27M derived: sum of 2 quarters · filed 2025-03-10 | $41.33M derived: sum of 3 quarters · filed 2025-03-10 | $57.06M 10-K · filed 2025-03-10 |
| 2023-09-30 | $13.26M 10-Q · filed 2024-11-07 | $30.32M derived: sum of 2 quarters · filed 2024-11-07 | $46.05M 10-Q · filed 2024-11-07 | $60.31M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $17.06M 10-Q · filed 2024-08-05 | $32.79M 10-Q · filed 2024-08-05 | $47.05M derived: sum of 3 quarters · filed 2024-08-05 | $61.35M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $15.73M 10-Q · filed 2024-05-08 | $29.98M derived: sum of 2 quarters · filed 2024-05-08 | $44.29M derived: sum of 3 quarters · filed 2024-05-08 | $55.58M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $14.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $28.56M derived: sum of 2 quarters · filed 2024-03-19 | $39.85M derived: sum of 3 quarters · filed 2024-03-19 | $48.61M 10-K · filed 2024-03-19 |
| 2022-09-30 | $14.30M 10-Q · filed 2023-11-13 | $25.60M derived: sum of 2 quarters · filed 2023-11-13 | $34.36M 10-Q · filed 2023-11-13 | $41.70M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $11.29M 10-Q · filed 2023-08-14 | $20.05M 10-Q · filed 2023-08-14 | $27.39M derived: sum of 3 quarters · filed 2023-08-14 | $35.93M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $8.76M 10-Q · filed 2023-05-09 | $16.10M derived: sum of 2 quarters · filed 2023-05-09 | $24.64M derived: sum of 3 quarters · filed 2023-05-09 | $29.66M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $7.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $15.88M derived: sum of 2 quarters · filed 2023-03-14 | $20.90M derived: sum of 3 quarters · filed 2023-03-14 | $24.78M 10-K · filed 2023-03-14 |
| 2021-09-30 | $8.54M 10-Q · filed 2022-11-03 | $13.57M derived: sum of 2 quarters · filed 2022-11-03 | $17.44M 10-Q · filed 2022-11-03 | $20.15M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.03M 10-Q · filed 2022-08-08 | $8.90M 10-Q · filed 2022-08-08 | $11.61M derived: sum of 3 quarters · filed 2022-08-08 | $13.52M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $3.88M 10-Q · filed 2022-05-09 | $6.58M derived: sum of 2 quarters · filed 2022-05-09 | $8.50M derived: sum of 3 quarters · filed 2022-05-09 | $9.56M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.62M derived: sum of 2 quarters · filed 2022-03-10 | $5.68M derived: sum of 3 quarters · filed 2022-03-10 | $6.06M 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.91M 10-Q · filed 2021-11-09 | $2.98M derived: sum of 2 quarters · filed 2021-11-09 | $3.35M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $1.06M 10-Q · filed 2021-08-09 | $1.44M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $377.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |